The Belfer Institute for Applied Cancer Science is accelerating cancer drug discovery through identification of novel targets via cutting-edge approaches, applying and evolving predictive oncology models, and integrating understanding of clinical response into drug discovery efforts. We are driven by our pursuit of translating world-class scientific discoveries into therapeutic results to significantly impact the lives of cancer patients.
In the News
Dr. Cloud Paweletz's publication - "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA" - cited in Oncology Times "Best Lung Cancer Research of 2014".
Molecular Cancer Research (MCR) editorial group has selected a Belfer publication - “Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3” - to be reprinted in a 2014 Must-Read compilation for AACR.
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.